Merck Wins Approval for HCV Drug

Xconomy New York — 

The FDA approved Merck’s (NYSE: MRK) treatment for chronic Hepatitis C virus (HCV), boceprevir (Victrelis), according to a press release. Boceprevir is the first of a new class of therapies known as HCV protease inhibitors, and it was approved to be used in combination with peginterferon alfa and ribavirin—two drugs that are considered the standard of care. Earlier this year, six analysts surveyed by Bloomberg predicted the drug’s sales would exceed $604 million per year by 2013.